DCM
VIR icon

DAFNA Capital Management’s Vir Biotechnology VIR Stock Holding History

DAFNA Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$734K – 90
2024
Q4 		$734K Buy
+100,000
New +$789K 0.19% 67

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DAFNA Capital Management's VIR Position: Q1 2025 in Review

DAFNA Capital Management sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 100,000 shares — an estimated $734K sold.

DAFNA Capital Management first reported a position in VIR in Q4 2024 and held it in 1 quarter. The position peaked at $734K in Q4 2024. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

  • DAFNA Capital Management reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 100,000 Vir Biotechnology shares in Q1 2025, an estimated $734K.
  • DAFNA Capital Management first reported a position in Vir Biotechnology in Q4 2024 and held it in 1 quarter.
  • DAFNA Capital Management's Vir Biotechnology position peaked at $734K in Q4 2024.
  • 233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.